Subject Index For Volume 33 Abdominal aneurysm, renal injury (abst) 623 Ablation anemia lessens hypertension and proteinuria (abst) . . . 375 deep nephrons (abst) 374 Acetate cAMP (abst) 219 succinate, effects in dialysis (abst) 228 Acetazolamide diabetic nephropathy (abst) 209 kinetics of anion exchange inhibitor (abst) 406 pH, transport (abst) 157 Acid amino, keto, disturbances of metabolism in RF (abst).. 139 amino, keto in diet for CRF (abst) 138 Acid-base abnormalities in cardiopulmonary arrest (abst) 185 status and dialysis symptoms 24:S-l17 status in ESRD (abst) 246 Acidification CsA in heart transplant (abst) 440 IMCD adaptation (abst) 398 proton locating ATPase 767 Acidosis acidification defect in distal renal tubular (abst) 130 ammonium excretion (abst) 183 carbicarb vs. bicarbonate in treatment (abst) 407 flow rate determines bicarbonate reabsorption (abst). .. 404 GLA protein and bone films in HD (abst) 232 glucose reabsorption, hyperglycemia (abst) 201 hyperchioremic (abst) 1040 interaction of glutamine and glutathione (abst) 390 metabolic, adaptation in BLM (abst) 405 metabolic, H-ATPase (abst) 404 metabolic, HCO3 reabsorption (abst) 404 metabolic, K depletion (abst) 405 Na dependent, distal acidification (abst) 194 phosphoenolpyruvate carboxykinase (abst) 177 respiratory (abst) 402 stimulates endocytic activity in CCD (abst) 406 Acinetobacter peritonitis (abst) 246 Actetate muscle high energy metabolites during HD (abst) 240 Acute Hantavirus nephropathy (abst) 356 Acute pancreatitis diagnosis (abst) 183 Acute renal failure after transplantation, perfused allograft (abst) 450 aminoglycoside nephrotoxicity 900 analgesic drugs (abst) 352 Aug II augments hypoxia (abst) 354 artery reconstruction (abst) 136 CAVH 24:S-159 CAVH in 100 patients (abst) 757 clearance of calcitriol 530 coagulation defects in uremia 24:S-l3 deferoxamine (abst) 363 djenkolic acid induced (abst) 359 DNA synthesis and polymerase activity (abst) 623 endotoxemic ARF, role of PAF (abst) 358 xl focus of tissue necrosis and gentamicin 84 glycerol induced, HgCl2 nephrotoxicity (abst) 352 histopathology of ischemic (abst) 366 hydroxyl radical in glycerol induced (abst) 368 hypoperfusion, gentamicin (abst) 357 induction and prevention of media-induced 699 mannitol induced (abst) 188 methylguanidine (abst) 371 nephrotoxic, loop diuretics (abst) 364 newborn, treatment (abst) 226 plasma exchange in multiple myeloma 1175 post-ischemia (abst) 369 reactive oxygen species do not mediate ischemic (abst) 370 renal recovery and survival (abst) 238 requiring dialysis (abst) 756 saline loading in uranium-induced 942 theophylline use in post-ischemic 24 urine sediment, childhood (abst) 1041 vasa recta blood flow (abst) 369 proto-oncogene expression (abst) 152 Acute renal insufficiency theophylline prevents hypoxemia-induced changes . .. 1078 Acute tubular necrosis clearance of calcitriol 530 culture of cells from urine (abst) 364 HgCl2 and K2Cr2O7 induced (abst) 365 Adenosine Al analog, TGF (abst) 263 analogues, tubuloglomerular feedback (abst) 413 cGMP a second messenger in renin inhibition 798 deaminase, ischemia (abst) 367 nucleotides in azotemic rabbits (abst) 382 receptor localization (abst) 256 renal function and vasa recta blood flow (abst) 276 triphosphate, thymidine incorporation (abst) 389 2C1, cAMP production and Na transport (abst) 419 Adenylate cyclase AVP in aging human CT (abst) 290 lithium (abst) 265 monoclonal antibody 543 mutations in Gs alpha (abst) 166 ADH glycerophosphoryicholine (abst) 255 inhibition, diuresis (abst) 432 Adhesive glycoproteins fibronectin (abst) 154 ADPKD adenocarcinoma, chronic HD (abst) 1040 continuous tissue culture (abst) 191 cystic kidneys 610 diphenyithiazole 1130 genetic marker for diagnosis (abst) 625 hyperuricemia in (abst) 211 influence of sex on liver disease (abst) 196 screening protocol (abst) 191 Adriamycin induced NS (abst) 261
31
Embed
Subject Index for Volume 33 · nephropathy, captopril and diltiazem (abst) 382 nephrosis, protein restriction (abst) 380 Aerobics in obese Zucker rats (abst) 326 Age catecholamaine
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Acidosisacidification defect in distal renal tubular (abst) 130ammonium excretion (abst) 183carbicarb vs. bicarbonate in treatment (abst) 407flow rate determines bicarbonate reabsorption (abst). .. 404GLA protein and bone films in HD (abst) 232glucose reabsorption, hyperglycemia (abst) 201hyperchioremic (abst) 1040interaction of glutamine and glutathione (abst) 390metabolic, adaptation in BLM (abst) 405metabolic, H-ATPase (abst) 404metabolic, HCO3 reabsorption (abst) 404metabolic, K depletion (abst) 405Na dependent, distal acidification (abst) 194
phosphoenolpyruvate carboxykinase (abst) 177
respiratory (abst) 402stimulates endocytic activity in CCD (abst) 406
Acinetobacter peritonitis (abst) 246Actetate
muscle high energy metabolites during HD (abst) 240Acute Hantavirus nephropathy (abst) 356Acute pancreatitis diagnosis (abst) 183Acute renal failure
after transplantation, perfused allograft (abst) 450
aminoglycoside nephrotoxicity 900analgesic drugs (abst) 352Aug II augments hypoxia (abst) 354artery reconstruction (abst) 136CAVH 24:S-159CAVH in 100 patients (abst) 757clearance of calcitriol 530coagulation defects in uremia 24:S-l3deferoxamine (abst) 363djenkolic acid induced (abst) 359DNA synthesis and polymerase activity (abst) 623endotoxemic ARF, role of PAF (abst) 358
xl
focus of tissue necrosis and gentamicin 84glycerol induced, HgCl2 nephrotoxicity (abst) 352histopathology of ischemic (abst) 366hydroxyl radical in glycerol induced (abst) 368hypoperfusion, gentamicin (abst) 357induction and prevention of media-induced 699mannitol induced (abst) 188
methylguanidine (abst) 371
nephrotoxic, loop diuretics (abst) 364newborn, treatment (abst) 226plasma exchange in multiple myeloma 1175post-ischemia (abst) 369reactive oxygen species do not mediate ischemic
(abst) 370renal recovery and survival (abst) 238requiring dialysis (abst) 756saline loading in uranium-induced 942theophylline use in post-ischemic 24urine sediment, childhood (abst) 1041vasa recta blood flow (abst) 369proto-oncogene expression (abst) 152
Acute tubular necrosisclearance of calcitriol 530culture of cells from urine (abst) 364HgCl2 and K2Cr2O7 induced (abst) 365
AdenosineAl analog, TGF (abst) 263analogues, tubuloglomerular feedback (abst) 413cGMP a second messenger in renin inhibition 798deaminase, ischemia (abst) 367nucleotides in azotemic rabbits (abst) 382receptor localization (abst) 256renal function and vasa recta blood flow (abst) 276triphosphate, thymidine incorporation (abst) 3892C1, cAMP production and Na transport (abst) 419
Adenylate cyclaseAVP in aging human CT (abst) 290lithium (abst) 265monoclonal antibody 543mutations in Gs alpha (abst) 166
ADPKDadenocarcinoma, chronic HD (abst) 1040continuous tissue culture (abst) 191
cystic kidneys 610diphenyithiazole 1130genetic marker for diagnosis (abst) 625hyperuricemia in (abst) 211influence of sex on liver disease (abst) 196
screening protocol (abst) 191
Adriamycininduced NS (abst) 261
Subject Index: Vol. 33 xli
nephropathy, captopril and diltiazem (abst) 382
nephrosis, protein restriction (abst) 380Aerobics in obese Zucker rats (abst) 326
Agecatecholamaine receptor binding 1073desensitization to PTH (abst) 348diet and sex response to immune injury 561
disease diagnosis, IgA (abst) 196
quality of life of old dialysis patients (abst) 758reduction in cytosolic Ca2 response (abst) 338
Agenesis vs. nephrectomy (abst) 143, 195AIDS
ARC and nephrotic syndrome (abst) 210associated nephropathy not in San Francisco (abst) . . . 202FSGS during (abst) 1041HIV antibodies in Danish dialysis patients (abst) 756HIV associated focal, segmental sclerosis (abst) 330HIV infections in HD (abst) 230HIV testing in chronic HD (abst) 235HIV transmission during HD (abst) 233hyponatremia, ARC (abst) 211nephropathy as initial manifestation (abst) 205peritonitis in HIV infected CAPD patients (abst) 245rapid renal failure (abst) 198
Alanine flux, CRF (abst) 395Albumin
extrarenal complications in nephrotic syndrome 1184
gene transcription (abst) 156
glycation of 673hemodynamics of excretion (abst) 434mild charge modification, excretion (abst) 433mild charge modification on excretion (abst) 1039optimal determination of excretion in diabetics
(abst) 214progressive decrease of in CAPD (abst) 757synthesis with dietary protein restriction (abst) 379synthesis, dietary protein (abst) 378
lysozymuria in Heymann's nephritis 787protein or enalapril (abst) 377
Alcohol abuse, mes IG deposition (abst) 385Aldose reductase
sorbitol in maintaining the medullary intracellularmilieu 635
AldosteroneADH, electrolytes (abst) 283
ATPase activity (abst) 278
biochemical pathway of (abst) 276
chronic acid loading (abst) 401
high potassium intake (abst) 270
K adaptation (abst) 427K and kaliuresis after acute loading of K (abst) 1037mechanism of increase in K conductance (abst) 429PCO2 enhance vanadate RB absorption (abst) 423voltage gated Ca currents in adrenal cells (abst) 291
19-nor, urinary excretion (abst) 273
Alfacalcidol, Ca iones (abst) 334Alkali secretion into urine (abst) 399Alkaline phosphatase in kidney (abst) 176Alkalosis
A characterization (abst) 330asymptomatic dialysis patients (abst) 236biocompatibility phenomenon of HD 24:S-35dialysis associated with long-term HD (abst) 234dialysis related 24:S-32HD associated (abst) 231
Analgesicdrugs, tubular damage (abst) 352nephropathy, biopsies in (abst) 145nephropathy, proteinuria is glomerular (abst) 141syndrome (abst) 136
Analogs of vitamin D3 (abst) 339Anaphylatoxin adsorption, HD (abst) 226Androgen
regulation of antiotensinogen messenger RNA (abst). . . 262Anemia
correction in chronic HD (abst) 237correction in hemodialysis (abst) 189erythropoiesis and erythropoietin blood levels (abst). . . 372erythropoietin, hemoglobin (abst) 217ESRD 983exercise capacity in HD (abst) 206human erythropoietin, hemodialysis (abst) 204hypertension and proteinuria in ablation (abst) 375microcytic, Al induced in HD (abst) 215peroxidation of polyunsaturated fatty acids (abst) 624recombinant human erythropoietin (abst) 232rHuEPO in HD (abst) 623risk factor in kidney biopsies (abst) 202
Angioplasty in elderly, RF (abst) 203Angiotensin
pressure-natriuresis relationship (abst)renin in hybridization (abst)renin, gene expression in (abst)tubuloglomerular feedback responses (abst)urinary excretion a marker of renal production
(abst) 1036Angiotensin converting enzyme
acute inhibition of (abst) 757cDNA isolation (abst) 150eliminatin of hippuran in RAS (abst) 760enalapril in diabetic nephropathy (abst) 178
hydroosmotic action of AVP (abst) 284inhibition, arterial stenosis (abst) 306inhibition, renal artery stenosis 1038inhibitor, suppresses growth of cells (abst) 296inhibitor, urea excreation (abst) 196partial protein sequence of mouse and bovine 652protein restriction, nephrosis (abst) 188reversible depression of Na,K-ATPase (abst) 303role in glomerulo-tubular balance (abst) 421
Angiotensin Iconverting enzyme, GFR (abst) 259
Angiotensin IIasymmetric reduction of receptor sites (abst) 304AVP in vascular smooth muscle cells (abst) 151
blockade reduces proteinuria (abst) 383causes formation of PAF (abst) 278CE!, reduced renal mass (abst) 384control of early proximal acidification (abst) 398disordered receptor regulation, diabetes (abst) 302down regulation of receptors in VSM (abst) 288hypertension (abst) 382Na reabsorption (abst) 129PGI on hemodynamics (abst) 413phospholipase A2, GTP binding protein (abst) 154platelet receptors, HD (abst) 230receptors and eicosanoid production (abst) 257sorbinil (abst) 380streptozotocin-induced diabetes (abst) 380thromboxane responses to (abst) 30812-lipoxygenase products (abst) 173
Angiotensinogenproduction by PTC (abst) 291role in glomerulo-tubular balance (abst) 421
Anionarginyl and histidyl groups (abst) 438
Anion exchanger, band 3 (abst) 168Anionic sites in MGN (abst) 627Ankyrin, spectrin and Na,K-ATPase (abst) 167Anoxia
alterations in Ca compartmentation (abst) 361cytosolic free Ca in renal damage (abst) 359metabolic responses to, hypoxia (abst) 390
(abst) 329anti-heparan sulfate proteoglycan (abst) 320anti-phospholipid, lupus nephritis (abst) 328circulating DNA and lupus nephritis 487epitope specific induction of proteinuria by 831
etylendioxid IgE (abst) 755glomerular, in human anti-GBM disease (abst) 135
Heymann nephritis antigen (abst) 251HLA removed in dialysis (abst) 4431gM anti-neutrophil, pulmonary hemorrhage (abst) .... 328immune complexes formation (abst)immune deposits in cryoglobulinemia (abst)induced mesangial cell lysis (abst)monoclonal anti-idiotype, DNA (abst)monoclonal, myeloma cast nephropathy (abst)monoclonal, nucleated cells in urine sediment (abst).new antigen system in progressive RF (abst)
411169163411
312626327199328332333
Subject Index: Vol. 33 xliii
noncationized, immune complexes (abst) 315
polyreactive anti-DNA, lupus nephritis (abst) 331serological diagnosis of Wegener' s granulomatosis
(abst) 760SGP-1151107, induction of proteinuria 818
hypotensive hemorrhage (abst) 369mineralocorticoid escape (abst) 430myocytes in fish (abst) 253Na excretion (abst) 284natriuresis (abst) 258osmotic water permeability (abst) 278plasma concentration in pregnancy (abst) 140poorly controlled diabetes (abst) 254post-ischemic acute failure (abst) 363
pregnancy (abst) 257
saline-expanded dogs (abst) 266salt adaptation in fish (abst) 289sodium retention during heart failure (abst) 272valsalva maneuver (abst) 2691-30 and 31-67 circulate in human (abst) 284
Atrial natriuretic peptideANF, dopamine, renal ischemia (abst) 259anti-ANP antibody, congestive heart failure (abst) 253augments excretion of Pi and Na (abst) 279blood glucose in insulin-dependent diabetes (abst) 759cirrhosis (abst) 257CRF (abst) 263
disappearance in dogs (abst) 275
down regulation of receptors (abst) 287
enalapril (abst) 1038
ESRD, periodic determinations (abst) 287gentamicin induced ARF (abst) 366GFR in hydronephrosis (abst) 358head out water immersion, cirrhotics (abst) 272hemodialysis in chronic uremic patients (abst) 758hypercalciuria (abst) 340hypervolemia in nephrotic humans (abst) 281
ligand, BP (abst) 271molecular forms in plasma and urine (abst) 201Na urinary excretion (abst) 373
• 1016290
143207
• . 281144347
• . 917
xliv Subject Index: Vol. 33
particulate guanylate cyclase activity (abst) 266relaxation of mesangial cell (abst) 285release during chronic Na loading (abst) 265renal effects of infusion (abst) 258renin-angiotensin system regulates (abst) 286sequential studies in baboons (abst) 140SIADH (abst) 192
superficial proximal tubule (abst) 289thyroid hormone status (abst) 290type 1 diabetes (abst) 270varying chronic Na intakes (abst) 285vasoconstriction in hydronephrotic (abst) 273vasporessin and renal nerves (abst) 26622Na uptake 291ligand, BP (abst) 271
Atriopeptin IllcGMP, renin (abst) 267hemodynamics and natriuresis (abst) 284
Autoantibodyanti-granulocyte cytoplasmic (abst) 329crescentic GN (abst) 313germline V gene utilization (abst) 325
B cell function in uremics (abst) 185B-endorphin in HD (abst) 221Bacteriuria and diaphragm use (abst) 132Band 3 anion exchanger (abst) 168Barium, K transport (abst) 420Baroreflex sensitivity and sex (abst) 411Bartter' s syndrome
hyperaldosteronism and nephrocalcinosis (abst) 146Basal membranes
ATP, ADP and AMP inhibition of cation channel(abst) 428
cellular heterogeneity (abst) 430dopamine receptors (abst) 433identification of C1HC03 in IC (abst) 408K channels (abst) 424measurement of potential (abst) 420vesicles, ionic mechanism of Na HCO3 (abst) 407
Bence Jones proteinuriaplasma exchange in ARF due to multiple myeloma. . . 1175
Benzoate, Gln ammoniagenesis (abst) 392Benzodiazepines, transport (abst) 431Beta
blockade, hypertension (abst)carboline and salt, BP (abst)endorphin, reabsorption (abst)receptor, cAMP (abst)subunit of renal Na-K ATPase (abst)
Beta-2-microglobulinallograft inflammatory cells (abst) 442amyloid deposits, chronic HD (abst) 242before and after HD (abst) 760circulating form in dialysis (abst) 332early detection of renal damage in children (abst) 137hemodialysis associated amyloid protein 24:S-30high flux HD (abst) 234in hemodialysis (abst) 755pitfalls in interpretation of changes, HD (abst) 225removal during dialysis (abst) 217skeletal lesions, amyloidosis (abst) 756synthesis in dialysis (abst) 228
Betaine synthesis, TM (abst) 433Bicarbonate
absorption by peptide hormones (abst) 400All, early proximal acidification (abst) 398electroneutral secretion, Cl transport (abst) 403flow rate determines reabsorption (abst) 404kinetics during biofiltration 24:S-120pKa in evaluating dialysate (abst) 623PTH analog inhibits action on HCO3 (abst) 341reabsorption in chronic metabolic acidosis (abst) 404reabsorption to feeding and NaHCO1 gavage (abst). . . . 404regulation of pH in PCT (abst) 403secretion (abst) 402transport in CT (abst) 387
adenosine on renal function (abst) 276autoregulation of flow and GFR (abst) 414azotemic anemic patients, hematocrit 184cooling during dialysis (abst) 221erythropoiesis and erythropoietin levels (abst) 372flow dynamic and UF kinetics in CAVH (abst) 236ionized Ca on systemic arterial pressure (abst) 295membrane interaction in HD (abst) 216mononuclear cells, immunoglobulin production
(abst)mononuclear cells, verapamil (abst)recirculation and effective clearances (abst)release of eicosanoids, dialyzer membranesrheology in IgA nephropathy (abst)transfusions in transplants critical (abst)uremic factor in ATPase (abst)uremic plasma on RBC insulin receptorvasa recta flow in ARF (abst)
297308275258156
318455219
24:S-82134455222378369191volume difference in hematuria (abst)
Blood pressureACE and Ca inhibitors, renal injury (abst) 129
276 and vasopressin changes in hypertension (abst) 294172 extracellular Ca2 modulates Vmc (abst) 304
Subject Index: Vol. 33 xlv
indirect ambulatory monitoring, hypertension (abst) . . . 308instruments for clinical research evaluated (abst) 145K depletion causes Na retention (abst) 299macronutrients (abst) 309nonvasorelaxant atrial peptide ligand (abst) 271portprandial changes during RD (abst) 238PTH level, in humans (abst) 308renorenal reflexes in SHR (abst) 299stress salt (abst) 308
Body mass index, excretion (abst) 383Bombesin, AYP action (abst) 282Bone
Al load and histological disease, HF and HD . . . . 24:S-168desferrioxamine, PTH (abst) 221disease in children on CAPD or CCPD 975disease in dialysis patients (abst) 337extrarenal complications of NS 1184forearm bone mineral content in dialysis (abst) 349formation rate in uremia (abst) 628lead in dialysis patients 601mineral content in transplanted patients (abst) 756preventing disease, CaCo3 and vitamin D3 24:S-178RAS oncogene transformed NIH3T3 cells (abst) 349remodeling, WR-2721 934turnover and 1 ,25-dihydroxycholecalciferol, K
EGF, cell proliferation (abst) 168hydronephrotic kidney sensitivity to 71PGE2 synthesis and Ca2 in arterioles (abst) 261
Brainmaturation in chilren with NS (abst) 182sex difference in Na transport (abst) 191
Branched-chain amino acidshemodynamics 91
Brush borderarginyl and histidyl groups, anion exchange (abst) 438fluorescence studies, gentamicin (abst) 360Na!H exchange in BBMV (abst) 430phosphonoformic acid binding protein from (abst) 160purification of protein from (abst) 398trypsin (abst) 408
Bubble cell (abst) 198Bumetanide
alkalosis impairs response to (abst) 200Butanol permeability, ADH (abst) 434
Caffeine, papillary damage (abst)Calcitonin
receptors (abst)release during HD inappropriate (abst)..salmon in human (abst)
Calcitiiolbioavailability (abst)clearance in ARFdeficiency in CRFhyperparathyroidism in CRF (abst)plasma kinetics, serum PTH (abst)status changes in hypertension (abst) .synthesis decreased in SHR (abst)women with osteoporosis (abst)
Calciumabsorption by amiloride (abst)absorption, Ca-ATPase (abst)absorption, thiazides stimulate
absorption, verapamil (abst) 343age-associated reduction in cytosolic (abst) 338alkalosis (abst) 338and K channels, cultured mesangial cells (abst) 164anoxia (abst) 359antagonists and CsA (abst) 454AVP sensitive cAMP metabolism by (abst) 268blood ionized, systemic arterial pressure (abst) 295calcitriol deficiency in CRF 722cAMP as second messengers for vasopressin (abst). . . . 286cAMP effect on Na transport (abst) 422carbonate, phosphate binder 24:S-l84cerebrospinal fluid, CSF Ca2 (abst) 297channel blockade (abst) 298channel blockade, PAF (abst) 413channel blockers, capillary pressure (abst) 370channels in basolateral membranes of PTC (abst) 171
chlorothiazide, furosemide, bumetanide (abst) 339chlorthalidone promotes mineral retention,
hypercalciuria 1140compartmentation during anoxia (abst) 361CsA uptake inhibited (abst) 451CsA on signalling and PGE production (abst) 361cytoplasmic inhibitor (abst) 622cytosolic free, diet and changes in medium (abst) 350cytosolic response to vasopressin in LLC-PK1
(abst) 289cytosolic, parathyroid cells, vitamin D3 850cytosolic, vitamin D3 (abst) 349dependency of hypotonic volume regulation (abst) . . . . 436dietary vs. supplemental, BP (abst) 302effects on Na flux (abst) 421epinephrine, PGE2 in MCT; Ni and AVP production
hypertension (abst) 300impaired efflux in SHR (abst) 300increases Na transport (abst) 423K and vitamin D in essential hypertension (abst) 627measurement of ionized (abst) 351
messenger system activation, PTH (abst) 340metabolic acidosis (abst) 351Mg flux and NaC1 (abst) 348mobilization by protein kinase C (abst) 277
138 overload differs from cell injury (abst) 359232 oxalate crystal binding in PCT (abst) 170350 oxalate effect on mitochondria (abst) 174
250oxytocin receptors in LLC-PKI cells (abst) 173
530 PGE induced elevation in MDCK cells (abst) 148
722 platelet cytosolic in essential hypertension (abst) 303
755 PTH-independent Pi uptake (abst) 348PTH, vitamin D3 in CRF 1049
294 set point, Al, dialysis (abst) 231
304 uptake by microsomes, maleate (abst) 165
345 urinary inhibitors modulated by 1005vitamin D, SHR (abst) 291
Calcium citratephosphate-binding agent for treatment of CRF 95
cAMPacetate (abst) 219apical membrane amplification (abst) 427beta-adrenergic stimulation (abst) 172beta-receptor mediated regulation (abst) 258catabolism, diabetes insipidus (abst) 264Ca2 signaling systems in UMR-106 cells (abst) 271demeclocycline, vasopressin (abst) 252independent of prostacyclin production (abst) 271pertussis toxin, somatostatin inhibition 536pH, and cell to cell communication (abst) 164regulates Cl conductance (abst) 421
Cancernephrocalcin in urine (abst) 209
Candida peritonitis, tuftsin (abst) 244CAPD
aceptic peritonitis (abst) 142bioavailability of calcitriol (abst) 250bone disease in children on, CCPD 975compared to HD 24:S-l23cortisol and corticosteroid binding (abst) 251
diabetic, intraperitonal insulin (abst) 246effluent, immunologic assessment (abst) 244exit site infections, catheter manipulation (abst) 243gram negative infections (abst) 249imipenem in treatment of (abst) 759long term effects, carbohydrate and lipid (abst) 1036long term experience with diabetes (abst) 251
lympho-monokine abnormalities (abst) 627"0" set (abst) 245
pediatric, lipoproteins in (abst) 248performed by relatives (abst) 759peritoneal transport of proteins, dextrans (abst) 1038
peritonitis (abst) 133peritonitis assiciated with bowel (abst) 133peritonitis in HIV infected (abst) 245peritonitis, IP vancomycin therapy (abst) 136
plasticizers exposure, membrane (abst) 246progressive decrease of serum albumin (abst) 757
teaching hospital experience (abst) 142
trimethoprim sulfamethoxazole prophylaxis (abst) 244ultrafiltration lower in children (abst) 247vancomycin superior to cefazolin in peritonitis
(abst) 245
Captoprildiltiazem in adriamycin nephropathy (abst) 382hypertension, renal arter stenosis, RDS (abst) 292iloprost and OKY 046, renal failure (abst) 281in normal subjects (abst) 282measurement of renin in hypertension (abst) 261NaCl reverses renal failure (abst) 364PG blockade in denervated kidneys (abst) 277
compare 2 in peritoneal dialysis (abst) 250exit site infections in CAPD (abst) 243internal jugular (abst) 218silicone, Dacron cuff (abst) 231subclavian, long-term dialysis (abst) 231tunnel infections reduced (abst) 245
CationATP, ADP and AMP inhibiton in BLM (abst) 428organic transport (abst) 436
CAVHblood flow dynamic and UF kinetics (abst) 236hemodynamics in (abst) 229in vitro simulation and math model 685postdilution vs. predilution (abst) 228report of 100 patients (abst) 757
CAVHDautomated (abst)effecient renal replacement therapy (abst)treatment for newborns with ARF (abst) .
CCK-8, cation transport (abst)cDNA ACE isolation (abst)CD4+ specific suppressor cell (abst)Cell
223233226138150443
ADH regulates volume (abst) 427anatomy of renin-secreting, APKD 1084bubble (abst) 198division, organelle inheritance (abst) 149EGF stimulates mitogenesis in medullary (abst) 255electrophysiological identification of, in CCT (abst).. .. 397epithelial, mesangial and endothelial lines 677functional heterogeneity in CCT (abst) 430isolation of principal and intercalated (abst) 155PHi determination in proximal tubular (abst) 163red production, anemia of ESRD 983red, serum folate levels in dialysis (abst) 756regulatory volume decrease in CCT (abst) 439rubidium uptake 642suppressor induction and inducer lymphokine (abst). . . 451swelling, propionate (abst) 418T suppressor inducer (abst) 450volume regulation in PT (abst) 428
Central pontine myelinolysis (abst) 204Cephalosporin
antibiotics (abst) 368aminoglycoside toxicity 900corrects phagocytic deficiency in HD (abst) 236, 1035protein binding (abst) 247
Cerebrospinal fluid, ANF (abst) 256
Subject Index: Vol. 33 xlvii
cGMPsecond messenger of adenosine, renin release 798
Channelsingle, PT (abst) 425
Childrenaccelerated growth following growth hormone (abst). . . 190ARC/AIDS and NS (abst) 210bone disease, CAPD or CCPD 975CsA induced remission of NS 729CSA, nephrotoxicity (abst) 214cytomegalovirus pneumonia (abst) 223early detection of renal damage (abst) 1378glomerular adaptation after nephrectomy in infants
(abst) 409growth hormone in uremics 45hearing loss in dialysis (abst) 249HUS favorable outcome (abst) 203hypercalciuria in hematuria (abst) 210IgG subclass depression, NS (abst) 333Jordanian, hypertension (abst) 305overview of pediatric nephrology 1016plasma infusion in HUS (abst) 206renal biopsy (abst) 142renal functional reserve in CRF (abst) 188steroid pattern to biopsy (abst) 207treatment of IgAN (abst) 181urine sediment and ARF (abst) 1041vesicoureteric reflux (abst) 179
ChlorideAll role in glomerulo-tubular balance (abst)base exchange regulates pH1 (abst)bicarbonate exchange regulates pH (abst)cAMP regulates conductance of (abst)channel activation, Ca signalling (abst)channel blocker, transport (abst)conductance defect, dialysis (abst)deplete in chronic metabolic acidosis (abst)depletion in K-Cl depletion alkalosis (abst)during euglycemic insulin antidiuresis (abst)extracellular ion concentration, 1P3, PGE2, Ca
(abst)fetal calf serum stimulates conductance (abst)K channel currents in BLM (abst)modulation of channel blocker effect (abst)reversible Cl dependent K flux (abst)transport in BLMV (abst)transport, electroneutral HCO3 secretion (abst)voltage dependant channel (abst)
Chlorophenylthio-cyclic AMP (abst)Chlorothiazide and GFR (abst)Chlorthialidone, hypercalciuria 1140Cholecystokinin and VIP (abst) 288
CholestryamineLDL catabolism (abst) 384
resin, PAN (abst) 376Choline dehydrogenase, IM (abst) 433
drug protein binding 996early, effect of protein (abst) 204enalapril long term (abst) 379fluid intake (abst) 381
growth, enalapril (abst) 374hair and serum Al in children (abst) 139hypermetabolism in remnant kidney (abst) 129infant nutritional management (abst) 193insulin release from pancreatic islets 1066
lisinopril (abst) 142low protein diets (abst) 376lupus nephritis, indices of outcome (abst) 331
nisoldipine (abst) 189oxydative metabolism of granulocytes (abst) 625PAN differences in rat strains 524
pericarditis 24:S-10predictors of progression (abst) 183
progression in solitary kidneys (abst) 206
proteolysis by thyroid hormone (abst) 391
pruritus (abst) 759
psychological symptoms 24:S-l8PTH and fatty acids oxidation in skeletal muscle 555PTH and vitamin D3 1049
rational therapeutic principles 116renal functional reserve in children (abst) 188
D-glucitol and aldose reductase role 635Dahl rat, hypertension and renal disease 1119Data base for tracking HD patients (abst) 220Decay accelerating factor (abst) 324Deferoxamine
ARF (abst) 363
mucormycosis, dialysis (abst) 238Dehydration
and azotemia (abst) 391
hypertension (abst) 307vasopressin and blood changes (abst) 141
cold hemodialysis (abst) 222decrease in Na-K ATPase activity (abst) 420determination of urine albumin excretion (abst) 214enalapril, GFR and RPF (abst) 189ESRD, racial disparity in survival (abst) 187fish oil (abst) 385genetic linkage, DNA marker (abst) 1035GFR, fluid volume and ANF (abst) 268glycation of albumin 673growth factor in nephropathy (abst) 201hyperfiltrating, PGE2, GFR and albumin (abst) 199hypernatremia in women (abst) 179hypertension alters PG response to (abst) 378hypouricemia (abst) 208improved prognosis for transplantation (abst) 441intracellular Na, role of glucose 792intralysosomal proteolytic enzymes, hypertrophy
(abst) 376long term experience in CAPD (abst) 251PAH (abst) 389PGE2 production in hypertension 1100
plasma clearances (abst) 187
protein kinase during renal growth (abst) 393
proteinuria determines prognosis (abst) 197
risks of nephropthy (abst) 193role of myo-inositol (abst) 372
Dialysisacetate and succinate (abst) 228acid-base status 24:S-l 17acinetobacter peritonitis (abst) 246
adequacy 24:S-92Al and Fe overload in chronic dialysis 24:S-163ARF requiring (abst) 756associated subclavian vein stenosis 1156asymptomatic patients, amyloidosis (abst) 236beta-adrenergic antagonists (abst) 182bicarbonate kinetics during biofiltration 24:S-120bone disease (abst) 337bone disease in children on CAPD or CCPD 975bone lead 601CAPD performed by relatives (abst) 759chloride conductance defect (abst) 379circulating form of /32M (abst) 332complement activation, membrane compatibility
(abst) 230computerization of REDY sorbent (abst) 238CPR attitudes (abst) 224daily, long-term clinical metabolism 24:S-137DFO test (abst) 625drainage bag size, transport 248endotoxin-like interleukin- 1 inducing activity 29ESRD choice of treatment according to cardiac
status 24:S-191familial risk of CRF in Blacks (abst) 204first use reactions 24:S-37forearm bone mineral content (abst) 349four different short techniques (abst) 236growth hormone in uremia 45hearing loss in children (abst) 249
herpes zoster (abst) 227
high flux membranes, /32M (abst) 217
high flux, azotemia and survival (abst) 239
high flux, polysulfone membrane (abst) 239HLA-antibodies removed (abst) 443
1 Subject Index: Vol. 33
hypercalcemic, PTH and bone Al levels (abst) 345hypersensitivity (abst) 224hypertonic hemodiafiltration 24:S-132indium-ill-leukocyte scan (abst) 223induced hypoxemia 24:S-57infant nutrition management (abst) 193
integrated approach to ESRD management 24:S-145intermittent ambulatory peritoneal (abst) 244intradialytic bicarbonate infusion (abst) 227long term effect of CAPD on carbohydrate, lipid
(abst) 1036low K bath (abst) 225lupus nephritis and ESRD (abst) 140membranes, lipoxygenase activity (abst) 240morbidity (abst) 625morbidity during short term (abst) 237National Cooperative Dialysis Study (abst) 227of the future 24:S-lOOpericarditis 24:S-10peritoneal catheter tunnel infections (abst) 245peritoneal transport of water, solutes and proteins
(abst) 1036phosphatidylcholine in peritoneal (abst) 247polyacrylonitrile vs. cuprammonium rayon (abst) 234polyelectrolytes as osmotic agents for 925polymorph superoxide production (abst) 248pruritus, iron deficiency (abst) 226quality of life in aged (abst) 758recirculation and effective clearances (abst) 219red cell and serum in (abst) 756Redy system (abst) 220related amyloidosis 24:S-32removal of phosphate in uremics 24:S-180renal failure, solute specific (abst) 250renal recovery and survival in ARF (abst) 238serum aluminum monitoring (abst) 218short, rapid blood flow (abst) 237somatic and psycosocial indicators (abst) 758
survival analysis (abst) 188survival long term (abst) 249synthesis of 2M (abst) 228TACurea and treatment schedules 24:S-105teaching hospital experience (abst) 142termination a cause of death (abst) 235transcutaneous gas monitoring (abst) 215volume and lymphatic flow in peritoneal (abst) 247water treatment (abst) 223
Wegener's granulomatosis recurs 1035Dialyzer
cuprophane, f32M (abst)cuprophane and polyacrylonitrile performancedifferent membranes, granulocyte elastasefistula recirculation (abst)high efficiency, shortens HD time (abst)high flux, specific features (abst)membrane and HD on pulmonary mechanics (abst).membranes, syndromes associated with use"0" set in CAPD (abst)on line sterile rinse of high flux (abst)release of eicosanoids from blood cellsurea and creatinine clearances (abst)
Diaphragm use and bacteriuria (abst)
Dietacute effects of meat meal on hemodynamics (abst). . . 1033age and sex, response to immune injury 561animal protein rich, kidney stone (abst) 335calorie restriction in CRF (abst) 386Ca2 in SHR (abst) 291cytosolic free Ca concentration (abst) 350different sources of protein in humans (abst) 411HD amino, keto acid levels (abst) 143intake pattern and glomerulosclerosis (abst) 385low protein, declining renal function (abst) 139PAN, proteinuria and early sclerosis (abst) 378phosphorus deprivation (abst) 337progression of early CRF (abst) 204renal response to acute protein meal (abst) 386sodium, aromatic L-amino acid decarboxylase (abst) . . 252zinc deficiency and uremia 1091
Dopamineexcretion, volume expansion, natriuresis (abst) .failure to induce natriuresis (abst).receptors on BLMV (abst)
Dopamine-l in hypertension (abst)..Dopaminergic stimuli on AVP (abst)Doxazosin and hemodynamics (abst)Drug protein binding, CRF
Edema, extrarenal complications, RF 1184Effusions due to decapsulation (abst) 199EGF, mitogenesis in cells (abst) 255
22024:S-5524: S-90
241235226220
24: S-49245241
24: S-82219132
757
415410433306283144996
Subject Index: Vol. 33 h
Eicosanoidcontrol of hemodynamics in cirrhosis (abst) 272production by goldfish kidney (abst) 273production, angiotensin II (abst) 257synthesis, anionic sites neutralized (abst) 282
Eicosapentaenoic acid diet, GN (abst) 285Elastase mediates injury (abst) 312Electrical property of GEC (abst) 172Electrolyte
catecholamine receptor binding 1073composition of tubular cells in gentamicin
nephrotoxicity 1107hyponatremia (abst) 186
Electrophoresisanalysis of efferent arteriole serum protein 1181
Electrophysiology of PT cells 508Enalapril
ACE inhibitor in diabetic nephropathy (abst) 178BP control, weight change in HD (abst) 299CRF (abst) 379diabetes, GFR and RPF (abst) 189growth, CRF (abst) 374HCTZ in genetically hypertensive dogs (abst) 293microalbuninuria (abst) 209Na and H20 balance in low sodium diet (abst) 292natriuresis of ANP (abst) 1038non-invasive measurement of hemodynamics of
(abst) 241daily dialysis 24:S-137dialysis related amyloidosis 24:S-32diphenylthiazole and ADPKD 1130erythropoietin (abst) 152glistening speckled appearance (abst) 197hematopoietic progenitor cell response 983heparin compared in HD and HF 890HIV staging system (abst) 242idiopathic membranous nephropathy, untreated
patients 708integrated approach to management 24:S-145intradialytic bicarbonate infusion (abst) 227lipids in diabetic and nondiabetic (abst) 216racial disparity, survival in diabetic (abst) 187
survival patterns in lupus nephritis (abst) 212teatment strategy according to cardiac status 24:S-191termination of dialysis as cause of death (abst) 235
End-stage renal failureCanadian public health (abst) 205cardiovascular changes during sleep (abst) 628comparison of membranes 24:S-44
EndocytosisNa solute cotransport (abst) 161
Endorphin, beta, reabsorption (abst) 275Endosome
Cl dependent H ATPase (abst) 159Endostreptosin in GN (abst) 180Endothelial cell
Epithelial growth factorbradykinin in proximal tubule cells (abst) 168
Epithelial polarity, ischemia (abst) 367Erythrocyte ferritin, HD (abst) 626Erythrocytes
C3b receptor in SLE (abst) 760Erythromycin
CsA simultaneously (abst) 448Erythropoiesis
deferoxamine, Al (abst) 215rHuEPO in transplant recipients (abst) 452
Erythropoietincardiac performance in HD patients (abst) 628chronic HD (abst) 218hypertensive effect (abst) 207mechanism of action (abst) 152pharmacokinetics of rHuEpo in HD (abst) 262recombinant, HD (abst) 232
Escherichia coliresistance (abst) 131
scarring (abst) 325
Essential hypertension, hemodynamics 875Ethylene oxide in HD 24:S-62Etylendioxid IgE antibodies (abst) 755Excretion
altered hemodynamics on albumin (abst) 434ammonium, proximal tubular acidosis (abst) 183extrarenal complications of nephrotic syndrome 1184magnesium, control mechanisms (abst) 140mild charge modification of albumin (abst) 433, 1039urinary angiotensin, marker of renal production
(abst) 1036urinary divalent cation, hypertension (abst) 29724-hour protein (abst) 142
Exerciseamplification by, signal of immune complexes (abst). . . 314 tolerance in HD patients (abst) 200
albumin transcription in liver of nephrotic rats (abst). . . . 156AVP in regulation in rat (abst) 285calcitonin release during HD (abst) 232Class II MHC expression, TIN (abst) 158cloning (abst) 155
early expression, hypertrophy or phyperplasia(abst) 168
molecular cloning of growth response (abst) 175non- H-2, murine apoferritin, ICGN (abst) 312PC-12 cells (abst) 162transcription by proximal tubule cultures, pH (abst) . . . 169variability of C4 number in nephrotic syndrome
(abst) 165Genetic marker for ADPKD (abst) 625Gentamicin
ARF, ANP protects against (abst) 366colchicine, cortical uptake (abst) 176electrolyte composition of tubular cells 1107fluorescence studies (abst) 360focus of tissue necrosis and ARF 84furosemide enhances D-glucose transport (abst) 363glomerular hemodynamics (abst) 353hypoperfusion ARF (abst) 357nephrotoxicity (abst) 355nephrotoxicity in rat neonates 36phosphatidylinositol cascade (abst) 360phospholipase C (abst) 362thyroid hormone, lysosomal volume (abst) 356x-ray imaging (abst) 355
Glomerular epithelial cellsheparan sulfate proteoglycans synthetized by (abst) ... 174membrane attack complex of complement (abst) 153
Glomerular filtration rateACE inhibition (abst) 259ANF in diabetics (abst) 268autoregulation of blood flow and (abst) 414BCAA and hemodynamics 91captopril in control of (abst) 305chlorothiazide (abst) 412contrast media-induced ARF 699handling of 99mTc-DMSA (abst) 1034
Subject Index: Vol. 33 liii
ischemic rate kidneys (abst) 1039protein intake determinant of (abst) 183recovery from partial ureteral obstruction 775theophylline in ischemic ARF 24
Glomeruliisolated for quantitation of immune deposits 89735S labelled proteoglycans (abst) 313
Graftcytotoxic antibodies and HLA B-DR matching (abst) .. 133
damaged kidneys in transplantation (abst) 146rejection, T cell immunization (abst) 135vs. host disease, murine (abst) 311
Granulocyteadherence changes, biocompatibility 24:S-68elastase, different dialyzer membranes 24:S-90
Granulocytopenia during HD (abst) 222Growth
ACE inhibitor suppresses growth of cells (abst) 296kidney, free cytosolic Ca2 (abst) 391PDGF, pH and Ca (abst) 156promoting factors after nephron loss (abst) 392renal, protein phosphorylation (abst) 159
(abst) 162epidermal excretion and dietary protein (abst) 376G proteins, thrombin and (abst) 160gene encoding in cisplatin nephrotoxicity (abst) 365human B cell (abst) 448platelet-derived, regulated by thrombin (abst) 148
Growth hormoneaccelerated growth following (abst) 190IGF-l, renal functin after GH injection (abst) 205in children with CRF (abst) 197Na retention (abst) 256phosphate reabsorption (abst) 344uremia 45
ANF (abst) 262ANF in rats with high output 656ANF prevents sodium retention (abst) 272AVP gene expression in congestive (abst) 270role of renal nerves (abst) 418
Helix pomatia agglutinin (abst) 320Hematocrit
azotemic anemic patients (abst) 184blood viscosity in azotemic patients (abst) 184dietary Ca and Fe interaction, SHR (abst) 302
liv Subject Index: Vol. 33
Hematuriahypercalciuria in childhood (abst) 210neoplasia (abst) 187overview of pediatric nephropathology 1016RBC volume difference (abst) 191
interleukin hypothesis 24:S-27interleukin-1 relevance to 24:S-21low molecular weight heparin 890measurement of thermal energy balance (abst) 235
membrane biocompatibility (abst) 217
membranes compared 24:S-44morbidity (abst) 625morbidity during short term (abst) 237muscle high energy metabolites (abst) 240muscle metabolism (abst) 239National Cooperative Dialysis Study (abst) 227neutrophil migration 24:S-86on-line sterile rinse of high flux (abst) 241optimum nutritional treatment, amino, keto levels
platelet angiotensin II receptors (abst) 230platelet lipoxygenase stimulation 24:S-80plethysmography (abst) 228poison treatment 735polyamide hemofilter (abst) 237polymorphonuclear leukocyte function (abst) 225postprandial BP during (abst) 238PTH and ionized Ca (abst) 337PTH, erythropoietin (abst) 224quality of life, r-EPO (abst) 242r-.HuEPO (abst) 218recombinant erythropoeitin (abst) 232, 240rHuEPO and anemia 623secondary hyperparathyroidism, CRF (abst) 1041
shortened time using high efficiency dialyzer (abst). . . . 235silicone catheter, Dacron cuff (abst) 231somatic and psychosocial indicators in chronic (abst) . . 758successful outcome of pregnancies (abst) 132
gentamicin (abst) 353glucagon and prostaglandins mediate amino acid rise
in 1147insulin-dependent diabetes mellitus (abst) 757irradiation of ureteral obstruction (abst) 358math model of tubuloglomerular feedback (abst) 412natriuresis of essential hypertension 875non-invasive measurement of enalapril (abst) 301
nonsteroidal antiinflammatory drugs (abst) 178
Subject Index: Vol. 33 lv
PAN and proteinuria (abst) 410paradoxical effects of insulin (abst) 410passive Heymann nephritis, C5A (abst) 755prednisolone increases glomerular permeability 1169pylonephritic renal scarring (abst) 195theophylline prevents hypoxemia-induced changes ... 1078vasopressin and oxytocin binding sites 959
HemofiltrationAl load and histological bone disease 24:S-168AN69S membrane 24:S-150in vitro simulation and math model 685low molecular weight hepann 890postdilution vs. predilution in CAVH (abst) 228protein loss during 24:S-114pump assisted, acute uremia 24:S-154ultrafiltration-pump assisted 24:S-157
HormoneADH excess, micropuncture comparison (abst) 141affecting calcium excretion (abst) 140antidiuretic, cobalt action (abst) 260control of division in proximal cells (abst) 175CRF and thyroid (abst) 195effects on NaC1 permeability (abst) 425growth, IGF-1 and function (abst) 205peptide, bicarbonate absorption (abst) 400protein-induced glomerular hyperfiltration 578PTH, vitamin D3 in CRF 1049requirements, hydrolases in PTC (abst) 170responsive glycan-phospholipid (abst) 175sex, in liver disease in ADPKD (abst) 196
thyroid, CRF (abst) 195vasoactive, dietary protein (abst) 260vasopressin and oxytocin binding sites 959
Horseradish peroxidasepermeability of mesangial cell region (abst) 174
HPLC, uremic toxin 24:S-4Human B cell growth factor (abst) 448Human immunodeficiency virus (abst) 205Hybridization, site of RAS (abst) 169Hydergine, CsA induced RF (abst) 1037Hydrogen transport in IMCD (abst) 398Hydrolases
hormonal requirements for sorting (abst) 170Hydrolysis
phosphoinositide, osmolality (abst) 392Hydronephrosis, ANP and GFR (abst) 358Hydroosmosis, AVP (abst) 390Hydroxyeicosatetraenoic acid (abst) 265Hydroxyl radical, ARF, glycerol (abst) 368Hyperaldosteronism
Bartter's syndrome (abst) 146Hypercalcemia
NaCI reabsorption (abst) 424vitamin D3 (abst) 347
HypercalciuriaANP levels in (abst) 340chlorthalidone promotes mineral retention 1140modulation by calcium of urinary inhibitors 1005vitamin D3, Ca (abst) 336
Hypercapniaenhancement of Na-H antiporter (abst) 407Na }{C03 cotransport (abst) 406
Hyperfiltrationfollowing nephrectomy in donors (abst) 761injury not occur in remnant kidney model (abst) 371protein-induced, hormones 578reversal in diabetic (abst) 387
Hyperglycemiaacidosis, glucose reabsorption (abst) 201glycation of albumin in normal and diabetic rats 673K, aldosterone (abst) 214
Hyperlipidemiaand renal injury (abst) 383extrarenal complications of NS 1184treatment reduces injury in obese rats 667
Hypermetabolismphosphate restriction in remnant kidney (abst) 129remnant kidney (abst) 129
Hypernatremiabrain and kidney inositol (abst) 435trimethylamines (abst) 194
Hyperoxaluria, transplantation (abst) 209Flyperparathyroid bone remodeling, RF 934Hyperparathyroidism
calcitriol deficiency in CRF 722hormonal disorders in CRF (abst) 133
Hyperperfusionhyperfiltration in proteinuria (abst) 212
lvi Subject Index: Vol. 33
Hyperplastic/atrophic changes in cysts 8Hypersensitivity to dialysis (abst) 224Hypertension
ACTH, renal artery pressure (abst) 430air jet stress in SHR (abst) 298alters PG response to diabetes (abst) 378ambulatory BP monitoring in diagnosis (abst) 308ANF vs. captopril (abst) 277angiotensin II dependent (abst) 382atenolol and exercise (abst) 144atherosclerosis, FSGS 917BP and vasopression (abst) 294BP, family history, Na transport (abst) 293Ca, P and vitamin D in essential (abst) 627calcitriol synthesis decreased in SHR (abst) 304calcium administration (abst) 300captopril, renal artery stenosis (abst) 292cation excretion (abst) 297cerebrospinal fluid and CSF Ca2 (abst) 297changes in calcitriol in SHR (abst) 294chronic hypernatremic dehydration (abst) 307dietary Ca and Fe interaction on hematocrit (abst) . . . . 302dietary NaCl restriction vs. diuretic therapy (abst) . . . . 292digoxin-like material levels (abst) 307diphenyithiazole, ADPKD 1130DOC-salt, nifedipine (abst) 374DOCA salt treatment on urinary prostaglandins 930dopamine 1 defect (abst) 306doxazosin and hemodynamics (abst) 144
enalapril on proteinuria (abst) 295genetic susceptibility to cyclosporine induced (abst) . . . 293genetics, enalapril and HCTZ in dogs (abst) 293hemodynamics in natriuresis of essential 875hyperinsulinemic glucose (abst) 298idiopathic membranous nephropathy, untreated 708impaired Ca efflux (abst) 300in Jordanian children (abst) 305injury, high K diet (abst) 307low sodium diet, H20 balance, enalapril (abst) 292Na-lithium counter transport (abst) 307nephrotoxic serum nephritis 53niledipine and vasoconstriction (abst) 294no true sublines of WKY rats in US (abst) 300PGE2 production in diabetic rats with 1100platelet cytosolic Ca (abst) 303post-transplant, captopril (abst) 441preceding neonatal thrombosis (abst) 145
proteinuria in IgA nephropathy 716recombinant erythropoietin (abst) 207renal disease, salt-sensitive Dahi rats 1119
renal plasma flow predicts captopril response (abst) . . . 294spontaneous, glucose intolerance (abst) 296time course of PT response to (abst) 409vascular reactivity and wall/lumen ratios (abst) 305vitamin D3 in essential (abst) 627vitamin D3, Ang 11 receptor sites (abst) 304volume and neural alterations in pre- (abst) 299
Hypoalbuminemiaextrarenal complications of NS 1184
Hypocalcemiaphosphorus handling (abst)
HyponatremiaAIDS and ARC (abst)correction of symptomatic (abst).electrolytes (abst)in women with diabetes (abst).rapid correction (abst)sexual difference in survival (abst)31P-NMR to study (abst)
Injuryabdominal aneurysm repair (abst) 623BP treatment, ACE inhibitor or Ca inhibitor
(abst) 129Ca-induced mitochondrial (abst) 362calcium channel blockers, capillary pressure (abst). . . . 370CE! and protein restriction (abst) 386cell Ca overload (abst) 359CsA induced chronic nephropathy 590cystic kidneys 610dietary sodium restriction, diuretics (abst) 292elastase mediates glomerular (abst) 312Fc receptor for IgG (abst) 322focal and segmental GS: analogy to atherosclerosis. . . . 917free radical-mediated postischemic, glutathione 843GBM necrosis and crescent organization 966glomerular, tumor necrosis factor (abst) 311
glomerulonephritis, reactive oxygen species (abst) . . . . 130glycine protects (abst) 357hyperfiltration, remnant kidney model (abst) 371hyperlipemia (abst) 383hyperlipidemia treatment reduces 667immune, diet, age and sex affects renal response to ... 561
ischemic, PGE2 (abst) 281
K permeability precedes, by HgC12 (abst) 354oxidant stress following ischemia 812PGE2 production in diabetic rats with hypertension... 1100polyethylene glycol (abst) 364progressive GS (abst) 374
proteinuria in IgA nephropathy 716reduced nephron mass and hypercholesterolemia
brain and kidney during hypernatremia (abst) 435leukotriene D4 binding in mesangial cells (abst) 253MDCK cells, transport (abst) 167tris, tetrakisphosphate pathway in CT (abst) 1711,4,5-trisphosphate, Ca2 channels in PTC (abst) 171
Instruments for BP measurement (abst) 145Insulin
apical, basolateral receptors (abst) 177hypertension and sensitivity to (abst) 298paradoxical hemodynamic effects (abst) 410proteolysis (abst) 396release from pancreatic islets 1066uremic plasma on RBC, receptor (abst) 378
altered in RD (abst) 216collagen synthesis in GEC (abst) 317endotoxin-like, in vitro dialysis 29gene expression in lupus nephritis (abst) 150natriuresis in conscious rats 1059proximal tubular glucose transport (abst) 319relevance in HD patients 24:S-21signal transduction pathway (abst) 324
L-dopa effect, Na-K pump (abst) 259L-thyroxine, TAL (abst) 362
L-triiodothyronine, Na-H (abst) 177Lactate
metabolism by TAL (abst) 395
Lambda light chain IgA (abst) 131
Lamininheterogeneity of in GBM (abst) 149
LDL catabolism, cholestyramine (abst) 384Lead
in bone with dialysis 601increases RBC Na!Li countertransport (abst) 293intoxication (abst) 143renal function risk (abst) 190
Lectinglomerular cells, staining (abst) 159
myeloma cast nephropathy (abst) 332Lesion
analysis of, after transplantation, CsA (abst) 448
catecholamine receptor binding, aging 1073
circulating DNA and lupus nephritis 487glomerular tip in NS (abst) 145glutathione transferase in the urine 571HD associated subclavian vein stenosis 1156
hypercholesterolemia 498interstitial nephritis in PAN nephrosis 14
liver; APKD (abst) 192
skeletal caused by f32-microglobulin amyloidosis(abst) 756
Leukemianephrotic syndrome in chronic lymphocytic (abst) 207
Leukopeniaxanthine oxidase deficiency (abst) 208
LeukotrieneB4, acute nephrotoxic serum nephritis (abst) 275D4 binding (abst) 253role of protein kinase C (abst) 254
Life plan, overview Marrakech meeting 24:S-2
Life support, withdrawing (abst) 758Light chain-related disease 881
Light chainsIgAN 584plasma exchange in ARF due to multiple myeloma . . . 1175
Lindane in uremics (abst) 199
Lipiddeposition, hypercholesterolemia 498ESRD(abst) 216lipoprotein alterations in nephrotic syndrome (abst) . . . 179membrane, erythrocyte cation transport (abst) 227
Lipopolysaccharide (abst) 316
Lipoproteinin children on CAPD (abst) 248
metabolism, lovastatin therapy in hyperlipidemia 1160
Lipoxygenaseactivity in HD (abst) 240during HD 24:S-80
Lisinoprilpharmacokinetics in CRF (abst) 142
Lithiumbiphasic effect (abst) 263clearance in man and dog (abst) 1034
nephrotoxicity 145tubular site of action of diuretics (abst) 1036
bradykinin Ca2 transients (abst) 153inositol transport (abst) 167membrane fluidity asymmetry (abst) 163pertussis toxin and cAMP (abst) 170PGE induced elevation in Ca2 concentration (abst)... 148
Mean arterial pressure, CAVH math model 685Medulla
electrolyte, urea and water transport (abst) 427purine nucleotide cycle (abst) 393
Medullary collecting ductacetazolamide effect on kinetics (abst) 406
MembraneAl removal, membranes compared 24:S-17lAN 69 in hemodiafiltration 24:S-135anaphylatoxins C3a and C5a adsorption (abst) 226AN69S in CAVH 24:S-150artificial, thromboxane release 24:S-75binding of complement (abst) 218compared in ESRD treatment 24:S-44complement activation and biocompatibility (abst) . . . . 230eosinophilia in HD 24:S-73GBM necrosis and crescent organization 966glomerular basement, pressor effects (abst) 295granular and basal cell, particle arrays (abst) 172luminal, water permeability (abst) 269lymphoid cells after contact with 24:S-53perfusion of human peritoneum (abst) 249peritoneal, plasticizer exposure (abst) 246peritoneal, transport properties of 24:S-107potential depolarized by Cl (abst) 168superoxide in cuprophane (abst) 224syndromes associated with use 24:S-49
Membranoproliferative glomeruloscierosisinflammation of JG distal tubule (abst) 1037
Membranous glomerulonephritis 627cyclophosphamide and prednisone (abst) 185predictors of progression (abst) 183
AVP volume relationships (abst) 211CsA induced remission in children 729cyclosporine in chi1dren (abst) 185extrarenal complications of 1184
gemfibrozil, hyperlipidemia (abst) 192
glomerular tip lesion (abst) 145IgG subclass depression in children (abst) 333indomethacin (abst) 381lipid and lipoprotein alterations (abst) 179lovastatin therapy in hyperlipidemia 1160
lymphocytic leukemia (abst) 207no change (abst) 196PGE2 and 6-keto-prostaglandin Fla (abst) 760phospholipids (abst) 628plasma volume and ANP (abst) 261
NephrotoxicityAIDS patients receiving pentamidine (abst) 198aminoglycoside 900aminoglycosides-induced in rat neonates 36contrast (abst) 208CsA in children (abst) 214CsA induced remission in children 729electrolyte composisiton of tubular cells in
gentamicin 1107genes encoding growth factors (abst) 365gentamicin cortical uptake (abst) 355HgC12, glycerol induced ARF (abst) 352infusion rate on CsA (abst) 442lithium in rabbits (abst) 145model of CsA (abst) 443reduction of CsA, 16-dimethyl prostaglandin E
Netilmicin toxicity in rat neonates 36Neuron disease, axonal conduction (abst) 625Neuropeptide Y inhibition (abst) 252Neutrophil
down regulation, HD (abst) 241migration, HD 24:S-86
New Zealand GN survey (abst) 133Nicardipine, renal effects (abst) 302Nifedipine
glomerular injury in hypertension (abst) 374propanolol, transplantation with CsA (abst) 367vasoconstriction in hypertension (abst) 294
NI}{3T3 cells, bone resorption (abst) 349Nisoldipine
progression of CRF (abst) 189Nomenclature, standard for the kidneyNorepinephrine
adrenergic receptors in CRF (abst) 295ANP reverses vasoconstriction (abst) 273brain synaptosomes in CRF, role of PTH (abst) 385CsA and vasoconstrictor effects of (abst) 442Na balance (abst) 296
Novobiocin, Na transport (abst) 416Nuclear magnetic resonance (abst) 397Nucleotide metabolism, protein (abst) 389Nutrition
urea kinetics applied to (abst) 215zinc deficiency and uremia 1091
hydrolysis (abst) 392luminal fluid, cytosolic Ca concentration (abst) 150
Osmolytedehydration in TM (abst) 434
levels in PCT (abst) 431Osmoregulation, sorbitol in medullary 635Osmotic agents for peritoneal dialysis 925Osteodystrophy
CrEDTA/TcMDP ratio (abst) 139vitamin D and keto acids (abst) 132
OsteomalaciaPTH on Al induced (abst) 343renal failure (abst) 187
Osteoporosiscalcitriol (abst) 345
Ouabainbioluminescent assay (abst) 306mediators of NaK ATPase response (abst) 424
Overdose, treatment of 735Oxalate
Ca dependent functions of mitochondria (abst) 174in HD (abst) 198vitamin C (abst) 382
Oxidative stress, pH, Ca2 (abst) 157Oxygen
consumption and oxidant stress, protein (abst) 381consumption by peritubular protein (abst) 423consumption, alpha-adrenergic agonist (abst) 392monocarboxylates in vivo (abst) 388
Oxygen free radicalinvolvement in decrease of ATPase activity 1038ischemia (abst) 354
Oxytocinreceptors, LLC-PK1 cell (abst) 173
vasopressin binding sites 959Ozolinone effect in dog (abst) 280
vitamin D3 on cytosolic Ca in dispersed cells 850Parathyroid glands, uremia (abst) 335Parathyroid hormone
acidification by PCT (abst) 169activation of Ca2 messenger system (abst) 341age, number of receptors (abst) 348Al activity in transplantation (abst) 346Al infusion (abst) 336alpha-hydroxylase activity (abst) 338ammoniagenesis in proximal tubule (abst) 389analog, proximal HCO3 (abst) 341Ca changes, Al bone disease after DFO (abst) 345calcitriol (abst) 339changes from ionized Ca (abst) 337CRF, fatty acids oxidation in skeletal muscle 555CRF, insulin release from pancreatic islets 1066desensitization of Ca2 response (abst) 340desferrioxamine, Al bone disease (abst) 221GTP-binding proteins (abst) 344HD, erythropoietin (abst) 224hypercalcemic dialysis, Al levels (abst) 345in uremia (abst) 219inhibits Na/H exchange (abst) 298
lxii Subject index. Vol. 33
level and BP in humans (abst) 308lymphocyte in uremics (abst) 197norepinephrine metabolism in brain (abst) 385secretion during renal failure (abst) 627skeletal response to calcemic action (abst) 341uremia, Al, Ca and change of Ca (abst) 337vitamin D3 CRF 10491-34 and 1-84 binding sites (abst) 3388-Br-cAMP effect on Ca2 (abst) 343
Particle arrays in membrane (abst) 172Particulate guanylate cyclase (abst) 266PC-12 cells, genes (abst) 162PDGF, growth, pH and Ca (abst) 156Pentamidine, nephrotoxicity (abst) 198Peptide
mitogens, regulate DNA synthesis (abst) 318mouse and bovine homology 652muramyl-dipeptide (abst) 439natriuresis after carotid artery traction (abst) 301
pHbicarbonate secretion (abst)Ca2 in oxidative stress (abst)C1 base exchange regulates (abst)intracellular, single LLC-PKI cells (abst)luminal, and AVP effect on K secretion (abst)measurement of intracellular, K depletion (abst)Na/H antiporters regulate (abst)NH3 metabolism in LLC-PK1 cells (abst)regulation of cell (abst)
steady state intracellular (abst) 403Phi determination in cells (abst) 163Phorbol esters
Polyelectrolytes in peritoneal dialysis 925Polyethylene glycol, injury (abst) 364Polyglobulism and CsA (abst) 452Polymeric IgA in IgAN (abst) 137Polymorph superoxide production (abst) 248Polymorphism, IgA GN (abst) 330Polymorphonuclear granulocytes (abst) 625Polymorphonuclear leukocytes (abst) 369Polysulfone
high flux dialysis membrane (abst) 239Potassium
adaptation, aldosterone (abst) 427aldosterone and kaliuresis after loading of (abst) 1037aldosterone role in high intake (abst) 270ammonia production by PT (abst) 405
225
hyperglycemia (abst) 214hypertensive injury (abst) 307mechanism of adaptation (abst) 418mechanism of aldosterone induced increase (abst) 429multiple pathways for transport (abst) 429permeability precedes injury by HgCl2 (abst) 354
permeability, uranyl nitrate (abst) 354plasma renin activity directly related to (abst) 288reversible Cl dependent flux (abst) 429stretch-activated channels (abst) 425vaspressin enhances secretion of (abst) 426
Potential, measurement of BM (abst) 420Predictors of GN outcome (abst) 143Prednisolone
conversion to alternate day therapy (abst) 449glomerular permeability to proteins in NS 1169
ammoniagenesis in acute respiratory alkalosis (abst)... 401ANF antagonizes release of (abs) 279blockade in denervated kidneys, captopril (abst) 277cAMP and Ca2 signaling systems (abst) 271Ca2, bradykinin in arterioles (abst) 261DOCA salt treatment on urinary 930GFR, albumin in diabetes (abst) 199glomerular production, GN (abst) 264glucagon, mediates amino acid induced rise in
vasopressin antagonists (abst) 251verapamil, GFR and CyA administration (abst) 355
Prostaglandin E1reversal of proteinuria (abst) 321
Prostaglandin E2cytoprotective effects of (abst) 281
epidermal growth factor mechanism (abst) 274inhibits Na-K-ATPase in IMCD (abst) 268production in diabetic rats with hypertension 1100renal denervation, natriuresis (abst) 280
bath, dialysis (abst)Cail channels in mesangial cells (abst)cell rubidium uptake indexes transport ofchannels in papillary surface epithelium (abst).C1 channel currents in BLM (abst)conductance, muzolimine (abst)depletion alkalosis, PHCO3 (abst)depletion and vasopressin (abst)depletion causes Na retention, high BP (abst)depletion, metabolic acidosis (abst)
164642424428424402431299405
lxiv Subject Index: Vol. 33
6-keto-prostaglandin Fla in NS (abst) 760Prostaglandin F2a
cytosolic pH, mesangial cells (abst) 154Protein
adriamycin nephrosis (abst) 380albumin synthesis (abst) 378alimentary, phosphorus restriction and CRF (abst) . .. 1041analysis of efferent arteriole serum, electrophoresis. .. 1181BP in diabetic nephropathy (abst) 190cell injury in ischemia (abst) 352complement, SP4O,40 in immune deposits (abst) 137
dexamethasone, heparan sulfate peoteoglycan (abst)... 161diabetic nephropathy, restriction of (abst) 184diacylglycerol, kinase C, transport of fluid and K
(abst) 272diet affects response to CyA (abst) 357diet, age, sex affects immune injury 561different sources in healthy humans (abst) 411distinct G, thrombin and growth factor (abst) 160DNA, protein synthesis after nephrectomy (abst) 380drug binding in CRF 996effect of diet on muscle protein synthesis (abst) 353glomerular disease and hypercholesterolemia 498GTP-binding, Ni, cAMP production (abst) 287induced hyperfiltration 578intake, GRF and creatinine generation (abst) 183kinase C modulates bradykinin, MDCK cells (abst).... 169kinase C, activators of (abst) 419kinase C, Ca mobilization (abst) 277kinase C, leukotrienes (abst) 254kinase C, renal growth (abst) 151
kinase C, vasopressin (abst) 153
kinase during diabetic renal growth (abst) 393kinase in glomerular eipthelial cells (abst) 170
kinase, glomerular epithelial cells (abst) 170lipoprotein abnormalities, IDD (abst) 213loss during hemofiltration 24:S-l 14low molecular weight (abst) 365low, diets and CRF (abst) 376membrane, complement activation (abst) 323mitotic response to high intake 662Na-K-ATPase activity modulated by 0-protein 150nucleotide metabolism (abst) 389oxygen consumption and oxidant stress (abst) 381PAF on glomerular permeability to (abst) 280partial sequence of ACE 652pathogenic role in systemic lupus EM (abst) 317
permeability in glomerulopathies (abst) 200phosphonoformic acid binding in BBM (abst) 160
phosphorylation during renal growth (abst) 159
PKD and diet (abst) 315prednisolone increases permeability to, NS 1169purification from BBMV (abst) 398
regulation of 02 consumption (abst) 423renal response to acute meal (abst) 386renin secretion, low protein diet (abst) 275
restriction, phosphate reabsorption (abst) 351
S and 0, clotting in nephrosis (abst) 210serum binding of cephalosporin during CAPD (abst). . . 247stimulation on renal function, CR1 (abst) 1033
analgesic nephropathy (abst) 141CsA reduces in anti-GBM nephritis (abst) 1039DNA effect on glomerular deposits (abst) 316enalapril in SHR (abst) 295epitope specific induction of 831high diet carbohydrate (abst) 326hyperperfusion vs. hyperfiltration (abst) 212lgA nephropathy 716IgA nephropathy (abst) 203induction by SGP-1 15/107 818long and short looped nephrons (abst) 325overview of pediatric nephropathology 1016PAN differences in rat strains 524proteases, ON, Avidin A (abst) 313protein overload, TIN (abst) 313reversal, PGE1, iloprost and TSI (abst) 321
thromboxane synthetase antagonist 77tubulointerstitial nephrosis and aminonucleoside
nephrosis 14
type 2 diabetes and prognosis (abst) 197Proteoglycan, 35S labelled (abst) 313
proteinuria (abst)nephropathy, proteinuria and early sclerosis (abst)nephrosis, cholestyramine resin (abst)nephrosis,converting enzyme inhibiton (abst)nephrosis, differences in rat strains
Pyelonephritic renal scarringhypervolemia, hormones and hemodynamics (abst).... 195
antibodies (abst)RDT, amyloid arthropathy (abst)Reactive oxygen species
do not mediate ischemic ARF (abst)PMN (abst)
Receptorapical and basolateral insulin (abst)beta-adrenergic, two classes of (abst).clearance, of ANF (abst)DA-1, 1251-SCH23982 (abst)down regulation of ANP (abst)
Recombinant erythropoietinabsorption of, peritoneal cavity (abst)HD (abst)quality of life in chronic HD (abst)urea kinetics (abst)
Renal decapsulationabdomen and perinephric effusions (abst) 199
Renal diseasecrack abuse in (abst) 181development of hypertension in salt-sensitive DahI . . . 1119molecular forms of ANP in plasma and urine (abst) . . . 201
Renal failureangioplasty in elderly patients (abst) 203calcitriol deficiency 722captopril, iloprost and OKY 046 (abst) 281chronic ON, severe proteinuria and TIN predict 14contrast media-induced 699contrast nephropathy (abst) 180insulin release from pancreatic islets 1066lithium 6 and 7 (abst) 357
acute inhibition of converting enzyme (abst) 757anatomy of secreting cell in AKPKD 1084
angiotensinogen, gene expression (abst) 163atriopeptin III, cGMP (abst) 267cGMP a second messenger of adenosine in inhibition .. . 798CsA effect on release (abst) 274CsA enhances secretion of (abst) 446cyclosporine A hypertension (abst) 267direct measurement in hypertension (abst) 261directly related to dietary K (abst) 288kinins mediate furosemide induced release (abst) 274low protein diet (abst) 275macula densa signal (abst) 256morphological events (abst) 145secretion and production of, isolated JG cells 947selective breeding for response in low Na diet (abst). . . 278serial plasma activity, pregnancy (abst) 306
Renin-angiotensin systemANP (abst) 286asymmetric reduction of Ang II receptor sites (abst). . . 304localization by hybridization of mRNAs (abst) 269saline loading on uranium-induced ARF 942diphenylthiazole develops renal cystic disease 1130
aldosterone on acidification (abst) 401alpha adrenergic stimulation (abst) 388ambystoma diluting segment (abst) 419ANF in regulation of excretion of (abst) 284ANP and urinary excretion in CRF (abst) 373ANP inhibits 22Na in IMCD (abst) 291aromatic L-amino acid decarboxlyase (abst) 252bicarbonate reabsorption to feeding and gavage (abst) . . . 404binding, UMR-106 cells (abst) 400concentration, Na-K ATPase 02 consumption (abst)... 426cotransport with H in BBM (abst) 178dependent uptake of Pi, phosphonoformic acid (abst) . . . 344dependent phosphate uptake (abst) 155distal acidification, acidosis (abst) 194DOCA treatment on urinary prostaglandins 930endocytosis and, cotransport in LLC-PK1 cells (abst)... 161flux, Ca (abst) 421glucocorticoid isoreceptor (abst) 170glucocorticoid isoreceptor lB (abst) 171
glucocorticoids regulate absorption (abst)growth hormone induced retention (abst)H exchange, PTH (abst)hydrogen exchange in BBMV (abst)inhibition, protein kinase C (abst)intracellular in diabetes, role of glucoseL-triiodothyronine, H exchange (abst)lithium clearance in man and dog (abst) 1034
loading in hypoproteinemia (abst) 1034loading, release of ANP (abst) 265mitotic response to high protein intake 662NaC1 reverses renal failure (abst) 364phosphate cotransport (abst) 342pump, K leak, volume regulation (abst) 418renal disease and development of hypertension, DahI
rat 1119risk of rapid treatment of hyponatremia (abst) 210selective breeding for renin response to, diet (abst). . . . 278
sensitive BP, family history of hypertension (abst) . . . . 293taurocholate in CCT 782transport by aldosterone and arginine vasotocin
(abst) 283transport in brain (abst) 191transport in uremic RBC (abst) 372tubular reabsorption, All (abst) 129
animal protein rich diet and formation of (abst) 335chlorthalidone promotes mineral retention 1140disease in Saudi Arabia (abst) 213formers, THP (abst) 342hypercalciuric, formers and vitamin D (abst) 343modulation by Ca of urinary inhibitors 1005
hyponatremia, sexual difference in (abst) 180Systemic lupus erythematosus
B-cell interleukin-2 (abst) 334circulating DNA 487Clq binding IgG (abst) 333C3b receptor activity (abst) 760pathogenic role of membrane protein (abst) 317
T cellactivation pathway, CsA (abst) 453antigen secreting epithelial cells (abst) 317crossmatch pretransplant (abst) 138immunization and graft rejection (abst) 135
Thymidine incorporation and ATP (abst) 389Thymocytes, cation transport (abst) 371
Thymosinanti-influenza antibody in HD (abst) 208
Thyroid hormone, gentamicin (abst) 356
Tight junctionopening, membrane fluidity, Na uptake (abst) 156
Tissue factor synthesis (abst) 327
Toxicityamphotericin B (abst) 360CyA, Ca and protease restriction (abst) 359electrophysiology of PT cells 508gentamicin and necrosis 84low molecular weight protein (abst) 365mitochondrial, cephalosporin antibiotics (abst) 368
Toxincoagulation defects in uremia 24:S-l3extracorporeal treatment of intoxications 735uremic 24:S-4
Training, clinical competence 608
Transcutaneous gas monitoring (abst) 215
Transfusion, Tx production (abst) 258Transluminal angioplasty, HD (abst) 230
cadaver donor age and survival of graft (abst) 450cardiac, ANP response (abst) 259combined liver-kidney, oxaluria (abst) 209coronary artery disease (abst) 136CsA pharmacokinetics (abst) 445CsA, prednisone and AZA in cadaveric (abst) 440damaged kidneys in living donor (abst) 146diabetic kidney prognosis (abst) 441donor specific transfusion (abst) 258DST vs. CsA (abst) 444eterminant of graft survival (abst) 444factors influencing function (abst) 454fractional excretion of Na, effect of CsA (abst) 451glutathione transferase in urine 571
graft loss caused by cyclosporine (abst) 146heroin associated nephropathy (abst) 442HLA-A2 recognition (abst) 446in USA not fair (abst) 446long term course of CsA-associated nephropathy 590long term predictors of graft survival (abst) 448magnetic resonance imaging (abst) 1040mononuclear cells and heart graft survival (abst) 445mucosal immunity (abst) 329myelofibrosis (abst) 447omega-3 polyunsaturated fatty acids (abst) 456oral bioavailability of CsA (abst) 455parathormone levels (abst) 452pediatric, CsA converted to AZA (abst) 445
Polyelectrolytes in peritoneal dialysis 925Polyethylene glycol, injury (abst) 364Polyglobulism and CsA (abst) 452Polymeric IgA in IgAN (abst) 137Polymorph superoxide production (abst) 248Polymorphism, IgA GN (abst) 330Polymorphonuclear granulocytes (abst) 625Polymorphonuclear leukocytes (abst) 369Polysulfone
high flux dialysis membrane (abst) 239Potassium
adaptation, aldosterone (abst) 427aldosterone and kaliuresis after loading of (abst) 1037aldosterone role in high intake (abst) 270ammonia production by PT (abst) 405
225
hyperglycemia (abst) 214hypertensive injury (abst) 307mechanism of adaptation (abst) 418mechanism of aldosterone induced increase (abst) 429multiple pathways for transport (abst) 429permeability precedes injury by HgCl2 (abst) 354
permeability, uranyl nitrate (abst) 354plasma renin activity directly related to (abst) 288reversible Cl dependent flux (abst) 429stretch-activated channels (abst) 425vaspressin enhances secretion of (abst) 426
Potential, measurement of BM (abst) 420Predictors of GN outcome (abst) 143Prednisolone
conversion to alternate day therapy (abst) 449glomerular permeability to proteins in NS 1169
PregnancyANF plasma concentrations in (abst) 140ANF, aldosterone and plasma volume (abst) 257chorionic gonadotropin (abst) 260hypertension and plasma renin activity (abst) 306IgA glomerulonephritis (abst) 136
Prostaglandinammoniagenesis in acute respiratory alkalosis (abst)... 401ANF antagonizes release of (abs) 279blockade in denervated kidneys, captopril (abst) 277cAMP and Ca2 signaling systems (abst) 271
Ca2, bradykinin in arterioles (abst) 261DOCA salt treatment on urinary 930GFR, albumin in diabetes (abst) 199glomerular production, GN (abst) 264glucagon, mediates amino acid induced rise in
hemodynamics 1147
hydronephrotic kidney sensitivity to bradykinin 71
Prostaglandin E1reversal of proteinuria (abst) 321
Prostaglandin E2cytoprotective effects of (abst) 281
epidermal growth factor mechanism (abst) 274inhibits Na-K-ATPase in IMCD (abst) 268production in diabetic rats with hypertension 1100renal denervation, natriuresis (abst) 280
bath, dialysis (abst)Cail channels in mesangial cells (abst)cell rubidium uptake indexes transport ofchannels in papillary surface epithelium (abst).C1 channel currents in BLM (abst)conductance, muzolimine (abst)depletion alkalosis, PHCO3 (abst)depletion and vasopressin (abst)depletion causes Na retention, high BP (abst)depletion, metabolic acidosis (abst)
164642424428424402431299405
Subject Index: Vol. 33 lxix
vitamin D3 in parathyroid glands (abst) 335zinc balance, zinc deficiency in 1091
Uremiclindane (abst) 199
nephropathy, insights (abst) 334PTH on lymphocyte in (abst) 197
Ureteral excision in rat (abst) 437Ureteral obstruction (abst) 358
management of complications during transplantation(abst) 1040
Urinary abnormalities in CRF (abst) 375Urine
acidification, proton translocating ATPases 767alkali secretion (abst) 399culture of cells, ATN (abst) 364glutathione transferase in the 571nitrogen and phosphate excretion and body mass index
(abst) 383Uroarthritis (abst) 761Urokinase
plasminogen activator (abst) 176
protein kinase (abst) 170Urosepsis, endotoxemia (abst) 212
VasopressinAVP in idiopathic nephrotic syndrome (abst) 211BP changes in hypertension (abst) 294Ca and cAMP as second messengers (abst) 286Ca and Na transport (abst) 417dehydration and rehydration (abst) 141demeclocycline effect on cAMP (abst) 252dialysis hypotension (abst) 222energy metabolism (abst) 255genetic linkage, diabetes and DNA marker (abst) . . . . 1035lithium effect on water flow (abst) 263luminal pH effects on K secretion (abst) 426NaC1 and osmotic water permeabilities (abst) 280neuropeptide Y inhibition (abst) 252oxytocin binding sites 959pertussis toxin, Vl receptor (abst) 257phorbol myristate acetata, A23 187 (abst) 252phosphoinositide hydrolysis in LLC-PK1 cells (abst).... 161renal hypertrophy (abst) 264renal prostaglandins (abst) 251resistance to, K depletion (abst) 431selectivity contracts arterioles (abst) 262sensitive cAMP metabolism by Ca (abst) 268sytosolic Ca, LLC-PK2 cells (abst) 289water channel in endocytic vesicles (abst) 175
action, pertussis toxin (abst) 264
enhances K excretion (abst) 426Vein stenosis, subclavian, HD 1156
Vesicoureteric reflux in children (abst) 179Vimentin filament in glomerulus (abst) 134Vitamin B6 deficiency, azotemic (abst) 388Vitamin C supplementation (abst) 382Vitamin D
experimental uremia (abst) 334keto acids in osteodystrophy (abst) 132metabolites after transplantation (abst) 623
Vitamin D3atherogenic role of (abst) 347clearance of calcitriol in ARF 530cytosolic Ca in parathyroid cells (abst) 349cytosolic calcium in parathyroid cells 850essential hypertension (abst) 627hypercalciuric stone formers (abst) 343increases plasma Al in RD 24:S-175interleukin 2 accumulation in T cells (abst) 346phosphorus levels regulated (abst) 346Pi transporter (abst) 350preventing bone disease 24:S-178prevents parathyroid cell proliferation (abst) 344PTH and CRF 1049synthesis and activity of analogs of (abst) 339synthesis in metabolic acidosis (abst) 342
Voltagedependent Cl channel (abst) 422
VolumeCa dependency of hypotonic regulation (abst) 436cell, ADH regulates (abst) 427hypotonic cell, cyclosporine (abst) 368peritoneal dialysate measurements 64regulation in PT (abst) 428regulation, Na pump, K leak (abst) 418regulatory cell decrease (abst) 439regulatory increase, CCT (abst) 436
Vi receptor antagonist (abst) 269
Waterchannel, vasopressin inducible (abst) 175
flow, energy metabolism during vasopressin (abst) .... 255
treatment in dialysis (abst) 223vesicles deliver conducting particles (abst) 261
Wegener' s granulomatosisdialysis and transplant (abst) 1035serological diagnosis of (abst) 760
Xanthine oxidase deficiency (abst) 208
Zincbalance in uremia and zinc deficiency 1091depletion, vitamin D3, phosphate diet (abst) 342
l-deamino-8-D-arginine-vasopressincorrects bleeding in uremia (abst) 142diabetes insipidus (abst) 182
1 ,25-dihydroxycholecalciferolbone turnover during treatment with phosphate